3 results
Approved WMOWill not start
Using a single formulation of PfPEBS LSP administered at two different doses, one of 5*g and the other one of 30*g, both adjuvanted with aluminium hydroxide, in two immunizations at 28 days interval, to evaluate a) the safety and immunogenicity (…
Approved WMOPending
The aims are: (1) to explore the feasibility of XRNT treatment in the Netherlands in terms of treatment participation and treatment retention; and (2) to study the mechanism of action of XRNT using pharmacoMRI and SPECT, and (3) to study the…
Approved WMOCompleted
To compare the effect of semaglutide 1.0 mg once-weekly versus exenatide extended release (ER) 2.0 mg once-weekly on glycaemic control after 56 weeks of treatment.